SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Traders are expressing significant skepticism and frustration regarding a campaign promise to issue a $5,000 dividend to every U.S. adult if Republicans win the upcoming midterms. The discussion is dominated by concerns over the plan's massive impact on national debt and the feasibility of the funding, with many users characterizing it as a desperate political bribe.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares are seeing active trading following the product launch event, where the company debuted its first foldable smartphone, the iPhone Duo, alongside the iPhone 18 Pro series. While some traders express skepticism regarding the device's high price point and late entry into the foldable market, many in the community are bullish, viewing the product as a potential revenue driver and a catalyst for future outperformance.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following news that it will be removed from the S&P 100 index, a development that has intensified debates among investors over the company's long-term turnaround prospects versus concerns about ongoing market share losses and brand management. The community remains deeply divided, with some traders viewing the current depressed valuation as a deep-value buying opportunity while others express skepticism, citing concerns about recent leadership changes and the sustainability of sales performance.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment shares are trending following a fiscal first-quarter earnings beat and the securing of a major U.S. Army production contract for its LOCUST laser weapon system. While many traders are bullish on the company's record backlog and its role in modern drone warfare, others remain cautious due to concerns over valuation, unchanged fiscal year guidance, and a bearish trend in forward earnings estimates.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The conversation is dominated by reactions to President Trump's campaign proposal of a $5,000 dividend for voters, which many traders are debating as a potential inflationary catalyst or political bribe. This discussion is intertwined with broader anxiety surrounding upcoming inflation data (PPI and CPI), rising crude oil prices, and climbing Treasury yields, leading to a cautious, split market sentiment.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven shares are reacting to the company's disclosure that the FDA has ordered a pause in enrollment for the BHV7000-303 epilepsy study, though dosing continues and the data readout remains on schedule for late 2026. While some investors view the pullback as a buying opportunity, others are expressing concern over the regulatory setback.

American Eagle Outfitters, Inc. operates retail stores and e-commerce channels offering apparel, accessories, and personal care products under the American Eagle and Aerie brands. It also operates the OFFL/NE by Aerie, Todd Snyder, and Unsubscribed brands. The firm operates stores in the United States, Canada, and Mexico and sells its products through international license partners. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle shares trended lower following an earnings release that disappointed the market, as investors discounted strong results driven by non-recurring tariff refunds and expressed concerns over flat same-store sales guidance for the core brand. While traders debated whether the sell-off was an overreaction given the company's profitability and Aerie segment momentum, many remain skeptical of the stock's near-term recovery prospects.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are surging following a positive AI market outlook presented by CFO Jean Hu, who highlighted significantly increased revenue expectations through 2027 and a massive multi-trillion dollar AI chip market forecast. Traders are reacting with a mix of intense bullish momentum and skepticism regarding valuation, while others closely watch technical levels and analyst price target upgrades for further guidance.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is currently trending as investors monitor the company's Phase 3 development of its lead MDD candidate, HLP003, and evaluate the impact of recent insider purchases and analyst price target hikes. Community sentiment is largely driven by optimism surrounding the late-stage trial progress, though some traders express skepticism regarding potential share dilution and historical management turnover.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics (IRD) shares surged after the company released positive Phase 1/2 clinical trial data for its gene therapy candidate, OPGx-BEST1, which demonstrated meaningful improvements in visual function. While the clinical results have driven significant bullish sentiment and speculation regarding a potential price rally, some market participants remain cautious, citing concerns over future share dilution and the early-stage nature of the data.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GPCR This should be down 20%+. Data is terrible and, once again, small molecules are shown to just not be in the same league as dual agonist peptide therapies. Will be very interesting to contrast $VKTX impending data release with this disappointment.

parrotineum

Sauce Man

kdii

Ashley Thomas

Maximus

dyrtydave

Atlas1978

Will C.

Rajesh

nlrmandate

StockTwits for iOS

Structure Therapeutics Inc - ADR

Viking Therapeutics Inc

 This should be down 20%+. Data is terrible and, once again, small molecules are shown to just not be in the same league as dual agonist peptide therapies. Will be very interesting to contrast 

 impending data release with this disappointment.

Jten10

@Jten10 Chill with the hyperbole. 16.2% body weight loss at 72 weeks is strong for an oral small-molecule GLP-1. High tolerability and no drug-induced liver injury also differentiates this from other small molecule GLP-1s.

Ian M

StockTwits Web

 Chill with the hyperbole. 16.2% body weight loss at 72 weeks is strong for an oral small-molecule GLP-1. High tolerability and no drug-induced liver injury also differentiates this from other small molecule GLP-1s.

Bryan B

@Bbbb44444 Grasping at straws. Where’s the AE and liver enzyme data? Otherwise, nothing that differentiates positively.

 Grasping at straws. Where’s the AE and liver enzyme data? Otherwise, nothing that differentiates positively.

@Jten10 @Bbbb44444 it did OK for a GLP-1/amylin.  16% at 70 weeks is better than 11% at ~60 weeks and 14% at 72 weeks, which is roughly what NVO and LLY oral GLP-1 did

 it did OK for a GLP-1/amylin.  16% at 70 weeks is better than 11% at ~60 weeks and 14% at 72 weeks, which is roughly what NVO and LLY oral GLP-1 did